目的 探討芪倍合劑聯(lián)合美沙拉嗪腸溶片治療活動期潰瘍性結(jié)腸炎的臨床療效。方法 選取2019年1月-2019年6月于新鄉(xiāng)醫(yī)學院第一附屬醫(yī)院門診及住院治療的96例活動期潰瘍性結(jié)腸炎患者作為研究對象，將所有潰瘍性結(jié)腸炎患者隨機分為對照組和治療組，每組各48例。對照組口服美沙拉嗪腸溶片，1 g/次，4次/d；治療組在對照組治療的基礎(chǔ)上口服芪倍合劑，50 mL/次，3次/d。兩組療程均為8周。觀察兩組患者的臨床療效，比較兩組的臨床癥狀緩解時間、血清白細胞介素-33（IL-33）、可溶性血清基質(zhì)裂解素（sST2）水平和復發(fā)率情況。結(jié)果 治療后，對照組、治療組的臨床總有效率分別為79.17%、93.75%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，治療組血便消失平均時間、腹瀉次數(shù)至少降低50%所需時間與對照組相比均顯著縮短，差異均具有統(tǒng)計學意義（P<0.05）。治療2、4、8周后，兩組患者血清IL-33、sST2水平同治療前相比均顯著下降（P<0.05）；且治療2、4、8周后，治療組患者血清IL-33、sST2水平均顯著低于同期對照組（P<0.05），差異均具有統(tǒng)計學意義（P<0.05）。隨訪3個月，對照組和治療組患者的復發(fā)率分別為30.56%、9.30%，差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 芪倍合劑聯(lián)合美沙拉嗪腸溶片治療活動期潰瘍性結(jié)腸炎的臨床療效較好，能迅速改善患者血便、腹瀉癥狀，降低機體的炎癥因子水平，有著良好的臨床應用價值。

Objective To explore the clinical efficacy of Qibei Mixture combined with Mesalazine Enteric-coated Tablet in treatment of active ulcerative colitis. Methods Patients (96 cases) with active ulcerative colitis in outpatient and inpatient of the First Affiliated Hospital of Xinxiang Medical University from January 2019 to June 2019 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were po administered with Mesalazine Enteric-coated Tablets, 1 g/time, four times daily. Patients in the treatment group were po administered with Qibei Mixture on the basis of the control group, 50 mL/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the remission time of clinical symptoms, the serum levels of IL-33 and sST2, and the relapse rate in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.17% and 93.75%, respectively, and there was difference between two groups (P<0.05). After treatment, the average time of bloody stool disappearance and the frequency of diarrhea decreased at least 50% than before treatment in the treatment group were significantly lower than those in the control group (P<0.05). After treatment for 2, 4, and 8 weeks, the serum levels of IL-33 and sST2 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of IL-33 and sST2 in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Follow up for 3 months, the clinical efficacies in the control and treatment groups were 30.56% and 9.30%, respectively, and there was difference between two groups (P<0.05). Conclusion Qibei Mixture combined with Mesalazine Enteric-coated Tablet has clinical curative effect in treatment of active ulcerative colitis, can rapidly improve the symptoms of bloody stool and diarrhea, reduce the levels of IL-33 and ST2, and has a good clinical application value.

R975

河南省科技攻關(guān)項目（192102310315）